Who Owns Artivion Company?

Artivion Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Artivion?

Artivion, Inc., formerly CryoLife, Inc., is a public company with a history rooted in innovative medical devices for cardiac and vascular procedures. Founded in 1984, it has grown into a significant player in the cardiovascular health sector.

Understanding Artivion's ownership is key to grasping its strategic direction and market influence. The company's journey from its founding to its current status as a publicly traded entity on the NYSE under AORT involves various stakeholders.

Who owns Artivion?

As a publicly traded company, Artivion's ownership is primarily distributed among its shareholders. As of July 22, 2025, the company has a market capitalization of approximately $1.43 billion. Institutional investors, such as mutual funds and pension funds, often hold significant portions of publicly traded companies. Individual investors also contribute to the ownership base. While specific major individual shareholders are not publicly disclosed in detail, the collective ownership by public shareholders drives the company's valuation and governance. The company's portfolio includes products like the Artivion Porter's Five Forces Analysis, which are central to its market presence.

Artivion, Inc., originally established as CryoLife in 1984, was founded by Steven Anderson and Robert McNally. Steven Anderson took on the role of President and CEO from the company's inception. While precise details on their initial equity split are not publicly available, their leadership was instrumental in shaping the company's early trajectory and operations.

Founding Vision The founders' vision centered on cryogenically preserved human tissues and medical devices for cardiac and vascular applications. This focus guided the company's initial direction and operational strategy. Early Leadership Steven Anderson served as the company's President and CEO from its founding. Robert McNally was the other co-founder, contributing to the establishment of the company's early framework. Initial Ownership Details Specifics regarding the initial equity distribution or exact shareholding percentages between the founders at the company's inception are not publicly detailed in available information. Early Investors Information on notable early backers, angel investors, or friends and family who acquired stakes during the initial phase is not explicitly provided in the search results. Founder Agreements Details concerning early agreements such as vesting schedules, buy-sell clauses, or founder exits are not explicitly mentioned in the provided sources. Ownership Disputes There is no specific information available regarding initial ownership disputes or buyouts among the founding team or early stakeholders.

The founding team's vision, focused on cryogenically preserved human tissues and medical devices for cardiac and vascular applications, guided the initial distribution of control within the company. While the exact mechanisms of this control distribution are not disclosed, the founders' strategic direction was paramount in establishing the company's early market position and Target Market of Artivion.

Artivion's Foundation

Artivion, initially known as CryoLife, was founded in 1984 by Steven Anderson and Robert McNally. Steven Anderson led the company as President and CEO from its inception.

• Founders: Steven Anderson and Robert McNally
• Founding Year: 1984
• Initial Focus: Cryogenically preserved human tissues and medical devices for cardiac and vascular applications
• Key Leadership: Steven Anderson (President and CEO)

Artivion SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Artivion, Inc., formerly known as CryoLife, Inc., transitioned to its current name and ticker symbol in January 2022, marking a significant evolution in its corporate identity. This rebranding underscored a strategic pivot towards specializing in aortic disease solutions. The company first became publicly traded on February 11, 1993, with an initial offering price of $10.00.

Institutional investors are the dominant force in Artivion's ownership structure, holding approximately 89.74% of the company's shares as of March 2025. Individual investors account for a smaller portion, around 6.76%. Among the major institutional stakeholders, BlackRock, Inc. reported a significant stake of 13.9%, representing 5,950,909 shares, as of June 30, 2025, with substantial voting authority. Other key institutional holders identified in recent 2025 filings include Vanguard Fiduciary Trust Co., Morgan Stanley Investment Management, Inc., and BNY Mellon Investment Adviser, Inc. Next Century Growth Investors LLC also maintained a notable ownership of 2.395% as of May 15, 2025. These holdings reflect the broad institutional interest in Artivion's market position and future growth prospects, as detailed in analyses of the Competitors Landscape of Artivion.

Artivion's Shareholder Profile

Institutional investors command the majority of Artivion's shares, indicating significant professional investment. Individual investors hold a smaller, but still present, segment of the ownership.

• Institutional Ownership: 89.74% (as of March 2025)
• Individual Ownership: 6.76% (as of March 2025)
• Major Institutional Holder: BlackRock, Inc. (13.9% stake as of June 30, 2025)
• Other Key Institutions: Vanguard, Morgan Stanley, BNY Mellon
• Notable Stakeholder: Next Century Growth Investors LLC (2.395% as of May 15, 2025)

Artivion PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors at Artivion, Inc. is instrumental in guiding the company’s strategic direction and governance. As of the 2025 proxy statement, J. Patrick Mackin holds the positions of Chairman, President, and Chief Executive Officer. The board is comprised of experienced independent directors, including Lead Independent Director Jeffrey H. Burbank, Daniel J. Bevevino, Thomas F. Ackerman, Marna P. Borgstrom, James W. Bullock, Elizabeth A. Hoff, Anthony B. Semedo, and Jon W. Salveson. The average tenure of the board members is approximately 8.8 years, reflecting a seasoned leadership team.

Artivion operates with a straightforward voting structure where each share of common stock carries one vote. This one-share-one-vote system ensures that voting power is directly proportional to the number of shares held, with no evidence of dual-class shares or special voting rights that could concentrate control. Shareholders of record as of March 17, 2025, were eligible to vote at the Annual Meeting on May 13, 2025. For those holding shares through a brokerage, a legal proxy is necessary to cast votes directly at the meeting. The company's governance appears stable, with no reported proxy battles or significant activist investor campaigns influencing its decision-making processes.

Understanding Artivion's Shareholder Structure

Artivion's corporate structure emphasizes a unified voting power for its shareholders. This approach ensures that the influence of each investor aligns directly with their equity stake.

• One-share-one-vote principle governs shareholder decisions.
• No dual-class share structures are in place.
• Shareholders of record on March 17, 2025, were eligible to vote.
• The company's Revenue Streams & Business Model of Artivion is supported by this governance framework.

Artivion Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, Artivion has seen significant shifts in its corporate identity and financial structure. The company rebranded from CryoLife, Inc. to Artivion, Inc. in January 2022, signaling a renewed focus on aortic disease solutions. These strategic adjustments are key to understanding the current Artivion ownership landscape.

Recent financial performance indicates steady growth, with first-quarter 2025 revenues reaching $99.0 million, a 2% increase year-over-year. The company anticipates full-year 2025 revenues between $423 million and $435 million, projecting an 11% to 14% growth on a constant currency basis. This financial trajectory is closely watched by its stakeholders, influencing the Artivion company owner profile.

Institutional Investor Dominance

As of March 2025, institutional investors held a substantial 89.74% of Artivion's shares. This highlights a strong reliance on institutional backing for the Artivion company owner structure.

Growing Institutional Interest

Between December 2024 and March 2025, there was an uptick in institutional holdings, with Foreign Institutional Investors increasing by 0.92% and Mutual Funds by 3.65%. This trend suggests increasing confidence in Artivion stock ownership.

Key Shareholder Presence

BlackRock, Inc. was a significant shareholder, holding 13.9% of the outstanding common stock as of June 30, 2025. This makes BlackRock a major player in the Artivion major shareholders list.

Strategic Financial Management

The company's recent convertible note exchange in May 2025, which involved $99.5 million in principal, demonstrates active management of its capital structure. This move is crucial for understanding the Artivion corporate structure and its future direction, as detailed in the Marketing Strategy of Artivion.

Artivion Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔